The functional role of platelets in the regulation of angiogenesis

Platelets

Volumn 26, Issue 3, 2015, Pages 199-211

  Walsh, Tony G ^a   Metharom, Pat ^b   Berndt, Michael C ^b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b CURTIN UNIVERSITY   (Australia)

Author keywords

Angiogenesis; Disease; Growth factors; Platelets; Thrombus; granule

Indexed keywords

PHOSPHOLIPID;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ATHEROSCLEROSIS; CELL GRANULE; DIABETIC RETINOPATHY; EMBRYO DEVELOPMENT; HEMOSTASIS; HUMAN; LYMPHATIC SYSTEM; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PLATELET MICROPARTICLE; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; THROMBOSIS; WOUND HEALING; ANIMAL; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; PHYSIOLOGY;

ANIMALS; BLOOD PLATELETS; HEMOSTASIS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; THROMBOSIS;

EID: 84925933664     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.3109/09537104.2014.909022     Document Type: Review

References (196)

1. Shattil SJ, Newman PJ. Integrins: Dynamic scaffolds for adhesion and signaling in platelets. Blood 2004;104:1606-1615.
2. Andrews RK, Gardiner EE, Shen Y, Berndt MC. Platelet interactions in thrombosis. IUBMB Life 2004;56:13-18.
3. Bizzozero. Su di un nuovo elemento morfologico del sangue dei mammiferi e sulla sua importanza nella trombosi e nella coagulazione. Osservatore Gazetta delle Cliniche 1881;17:785-787.
4. Brewer DB. Max Schultze (1865), G. Bizzozero (1882) and the discovery of the platelet. Br J Haematol 2006;133:251-258.
5. Sun NC, McAfee WM, Hum GJ, Weiner JM. Hemostatic abnormalities in malignancy, a prospective study of one hundred eight patients. Part I. Coagulation studies. Am J Clin Pathol 1979; 71:10-16.
6. Tesselaar ME, Romijn FP, Van Der Linden IK, Prins FA, Bertina RM, Osanto S. Microparticle-associated tissue factor activity: A link between cancer and thrombosis? J Thromb Haemost 2007;5:520-527.
7. Pinedo HM, Verheul HM, D'Amato RJ, Folkman J. Involvement of platelets in tumour angiogenesis? Lancet 1998;352:1775-1777.
8. Pipili-Synetos E, Papadimitriou E, Maragoudakis ME. Evidence that platelets promote tube formation by endothelial cells on matrigel. Br J Pharmacol 1998;125:1252-1257.
9. Andrews RK, Berndt MC. Platelet physiology and thrombosis. Thromb Res 2004;114:447-453.
10. Nieswandt B, Watson SP. Platelet-collagen interaction: Is GPVI the central receptor? Blood 2003;102:449-461.
11. Ruggeri ZM, Mendolicchio GL. Adhesion mechanisms in platelet function. Circ Res 2007;100:1673-1685.
12. De Meyer SF, Deckmyn H, Vanhoorelbeke K. von Willebrand factor to the rescue. Blood 2009;113:5049-5057.
13. Gardiner EE, Arthur JF, Shen Y, Karunakaran D, Moore LA, Am Esch 2nd JS,, Andrews RK, Berndt MC. GPIbalpha-selective activation of platelets induces platelet signaling events comparable to GPVI activation events. Platelets 2010;21:244-252.
14. Ruggeri ZM. Structure and function of von Willebrand factor. Thromb Haemost 1999;82:576-584.
15. Andrews RK, Gardiner EE, Shen Y, Whisstock JC, Berndt MC. Glycoprotein Ib-IX-V. Int J Biochem Cell Biol 2003;35:1170-1174.
16. Lopez JA, Andrews RK, Afshar-Kharghan V, Berndt MC. Bernard-Soulier syndrome. Blood 1998;91:4397-4418.
17. Fredrickson BJ, Dong JF, McIntire LV, Lopez JA. Shear-dependent rolling on von Willebrand factor of mammalian cells expressing the platelet glycoprotein Ib-IX-V complex. Blood 1998;92:3684-3693.
18. Farndale RW, Sixma JJ, Barnes MJ, de Groot PG. The role of collagen in thrombosis and hemostasis. J Thromb Haemost 2004;2: 561-573.
19. Kato K, Kanaji T, Russell S, Kunicki TJ, Furihata K, Kanaji S, Marchese P, Reininger A, Ruggeri ZM, Ware J. The contribution of glycoprotein VI to stable platelet adhesion and thrombus formation illustrated by targeted gene deletion. Blood 2003;102:1701-1707.
20. Massberg S, Gawaz M, Gruner S, Schulte V, Konrad I, Zohlnhofer D, Heinzmann U, Nieswandt B. A crucial role of glycoprotein VI for platelet recruitment to the injured arterial wall in vivo. J Exp Med 2003;197:41-49.
21. Nieswandt B, Brakebusch C, Bergmeier W, Schulte V, Bouvard D, Mokhtari-Nejad R, Lindhout T, Heemskerk JW, Zirngibl H, Fässler R. Glycoprotein VI but not alpha2beta1 integrin is essential for platelet interaction with collagen. Embo J 2001;20:2120-2130.
22. Li Z, Zhang G, Le Breton GC, Gao X, Malik AB, Du X. Two waves of platelet secretion induced by thromboxane A2 receptor and a critical role for phosphoinositide 3-kinases. J Biol Chem 2003;278: 30725-30731.
23. Gachet C. ADP receptors of platelets and their inhibition. Thromb Haemost 2001;86:222-232.
24. Broos K, Feys HB, De Meyer SF, Vanhoorelbeke K, Deckmyn H. Platelets at work in primary hemostasis. Blood Rev 2011;25: 155-167.
25. Monroe DM, Hoffman M, Roberts HR. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol 2002;22:1381-1389.
26. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005;438:932-936.
27. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-257.
28. Folkman J. Angiogenesis: An organizing principle for drug discovery? Nat Rev Drug Discov 2007;6:273-286.
29. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003;9: 653-660.
30. Kisucka J, Butterfield CE, Duda DG, Eichenberger SC, Saffaripour S, Ware J, Ruggeri ZM, Jain RK, Folkman J, Wagner DD. Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage. Proc Natl Acad Sci USA 2006;103:855-860.
31. Brill A, Elinav H, Varon D. Differential role of platelet granular mediators in angiogenesis. Cardiovasc Res 2004;63:226-235.
32. Frojmovic MM, Milton JG. Human platelet size, shape, and related functions in health and disease. Physiol Rev 1982;62:185-261.
33. Klement GL, Yip TT, Cassiola F, Kikuchi L, Cervi D, Podust V, Italiano JE, Wheatley E, Abou-Slaybi A, Bender E, et al. Platelets actively sequester angiogenesis regulators. Blood 2009;113: 2835-2842.
34. Blair P, Flaumenhaft R. Platelet alpha-granules: Basic biology and clinical correlates. Blood Rev 2009;23:177-189.
35. Diacovo TG, Puri KD, Warnock RA, Springer TA, von Andrian UH. Platelet-mediated lymphocyte delivery to high endothelial venules. Science 1996;273:252-255.
36. Huo Y, Schober A, Forlow SB, Smith DF, Hyman MC, Jung S, Littman DR, Weber C, Ley K. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med 2003;9:61-67.
37. Moulin V, Lawny F, Barritault D, Caruelle JP. Platelet releasate treatment improves skin healing in diabetic rats through endogenous growth factor secretion. Cell Mol Biol (Noisy-le-grand) 1998;44: 961-971.
38. Kaplan DR, Chao FC, Stiles CD, Antoniades HN, Scher CD. Platelet alpha granules contain a growth factor for fibroblasts. Blood 1979; 53:1043-1052.
39. Wartiovaara U, Salven P, Mikkola H, Lassila R, Kaukonen J, Joukov V, Orpana A, Ristimäki A, Heikinheimo M, Joensuu H, et al. Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation. Thromb Haemost 1998;80: 171-175.
40. Ben-Ezra J, Sheibani K, Hwang DL, Lev-Ran A. Megakaryocyte synthesis is the source of epidermal growth factor in human platelets. Am J Pathol 1990;137:755-759.
41. Browder T, Folkman J, Pirie-Shepherd S. The hemostatic system as a regulator of angiogenesis. J Biol Chem 2000;275:1521-1524.
42. Karey KP, Sirbasku DA. Human platelet-derived mitogens. II. Subcellular localization of insulinlike growth factor I to the alphagranule and release in response to thrombin. Blood 1989;74: 1093-1100.
43. Gale NW, Yancopoulos GD. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev 1999;13:1055-1066.
44. Weltermann A, Wolzt M, Petersmann K, Czerni C, Graselli U, Lechner K, Kyrle PA. Large amounts of vascular endothelial growth factor at the site of hemostatic plug formation in vivo. Arterioscler Thromb Vasc Biol 1999;19:1757-1760.
45. Etulain J, Fondevila C, Negrotto S, Schattner M. Platelet-mediated angiogenesis is independent of VEGF and fully inhibited by aspirin. Br J Pharmacol 2013;170:255-265.
46. Jimenez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL, Bouck N. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med 2000;6:41-48.
47. Kopp HG, Hooper AT, Broekman MJ, Avecilla ST, Petit I, Luo M, Milde T, Ramos CA, Zhang F, Kopp T, et al. Thrombospondins deployed by thrombopoietic cells determine angiogenic switch and extent of revascularization. J Clin Invest 2006;116:3277-3291.
48. Feng W, Madajka M, Kerr BA, Mahabeleshwar GH, Whiteheart SW, Byzova TV. A novel role for platelet secretion in angiogenesis: Mediating bone marrow-derived cell mobilization and homing. Blood 2011;117:3893-3902.
49. Huang Z, Rahman MF, Jiang L, Xie H, Hu H, Lui WO, Li N. Thrombin induces de novo protein synthesis of SDF-1alpha but not angiostatin in human platelets. J Thromb Haemost 2012;10: 2202-2205.
50. Maione TE, Gray GS, Petro J, Hunt AJ, Donner AL, Bauer SI, Carson HF, Sharpe RJ. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 1990;247: 77-79.
51. Date K, Matsumoto K, Kuba K, Shimura H, Tanaka M, Nakamura T. Inhibition of tumor growth and invasion by a four-kringle antagonist (HGF/NK4) for hepatocyte growth factor. Oncogene 1998;17: 3045-3054.
52. Jurasz P, Alonso D, Castro-Blanco S, Murad F, Radomski MW. Generation and role of angiostatin in human platelets. Blood 2003; 102:3217-3223.
53. Ma L, Perini R, McKnight W, Dicay M, Klein A, Hollenberg MD, Wallace JL. Proteinase-activated receptors 1 and 4 counter-regulate endostatin and VEGF release from human platelets. Proc Natl Acad Sci USA 2005;102:216-220.
54. Ikenaka Y, Yoshiji H, Kuriyama S, Yoshii J, Noguchi R, Tsujinoue H, Yanase K, Namisaki T, Imazu H, Masaki T, et al. Tissue inhibitor of metalloproteinases-1 (TIMP-1) inhibits tumor growth and angiogenesis in the TIMP-1 transgenic mouse model. Int J Cancer 2003;105:340-346.
55. Italiano Jr JE,., Richardson JL, Patel-Hett S, Battinelli E, Zaslavsky A, Short S, Ryeom S, Folkman J, Klement GL. Angiogenesis is regulated by a novel mechanism: Pro-and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood 2008;111:1227-1233.
56. Kamykowski J, Carlton P, Sehgal S, Storrie B. Quantitative immunofluorescence mapping reveals little functional coclustering of proteins within platelet alpha-granules. Blood 2011;118:1370-1373.
57. van Nispen tot Pannerden H, de Haas F, Geerts W, Posthuma G, van Dijk S, Heijnen HF. The platelet interior revisited: Electron tomography reveals tubular alpha-granule subtypes. Blood 2010; 116:1147-1156.
58. Jonnalagadda D, Izu LT, Whiteheart SW. Platelet secretion is kinetically heterogeneous in an agonist-responsive manner. Blood 2012;120:5209-5216.
59. Horstman LL, Ahn YS. Platelet microparticles: A wide-angle perspective. Crit Rev Oncol Hematol 1999;30:111-142.
60. Berckmans RJ, Nieuwland R, Boing AN, Romijn FP, Hack CE, Sturk A. Cell-derived microparticles circulate in healthy humans and support low grade thrombin generation. Thromb Haemost 2001;85: 639-646.
61. Sims PJ, Wiedmer T, Esmon CT, Weiss HJ, Shattil SJ. Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in Scott syndrome: An isolated defect in platelet procoagulant activity. J Biol Chem 1989;264: 17049-17057.
62. Italiano Jr JE, Mairuhu AT, Flaumenhaft R. Clinical relevance of microparticles from platelets and megakaryocytes. Curr Opin Hematol 2010;17:578-584.
63. Kim HK, Song KS, Park YS, Kang YH, Lee YJ, Lee KR, Kim HK, Ryu KW, Bae JM, Kim S. Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: Possible role of a metastasis predictor. Eur J Cancer 2003; 39:184-191.
64. Weber A, Koppen HO, Schror K. Platelet-derived microparticles stimulate coronary artery smooth muscle cell mitogenesis by a PDGF-independent mechanism. Thromb Res 2000;98:461-466.
65. Baj-Krzyworzeka M, Majka M, Pratico D, Ratajczak J, Vilaire G, Kijowski J, Reca R, Janowska-Wieczorek A, Ratajczak MZ. Plateletderived microparticles stimulate proliferation, #survival, |adhesion, and chemotaxis of hematopoietic cells. Exp Hematol 2002;30: 450-459.
66. Kim HK, Song KS, Chung JH, Lee KR, Lee SN. Platelet microparticles induce angiogenesis in vitro. Br J Haematol 2004; 124:376-384.
67. Brill A, Dashevsky O, Rivo J, Gozal Y, Varon D. Platelet-derived microparticles induce angiogenesis and stimulate post-ischemic revascularization. Cardiovasc Res 2005;67:30-38.
68. Hayon Y, Dashevsky O, Shai E, Brill A, Varon D, Leker RR. Platelet microparticles induce angiogenesis and neurogenesis after cerebral ischemia. Curr Neurovasc Res 2012;9:185-192.
69. Janowska-Wieczorek A, Majka M, Kijowski J, Baj-Krzyworzeka M, Reca R, Turner AR, Ratajczak J, Emerson SG, Kowalska MA, Ratajczak MZ. Platelet-derived microparticles bind to hematopoietic stem/progenitor cells and enhance their engraftment. Blood 2001;98: 3143-3149.
70. Ohtsuka M, Sasaki K, Ueno T, Seki R, Nakayoshi T, Koiwaya H, Toyama Y, Yokoyama S, Mitsutake Y, Chibana H, et al. Plateletderived microparticles augment the adhesion and neovascularization capacities of circulating angiogenic cells obtained from atherosclerotic patients. Atherosclerosis 2013;227:275-282.
71. Mallat Z, Benamer H, Hugel B, Benessiano J, Steg PG, Freyssinet JM, Tedgui A. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation 2000;101:841-843.
72. English D, Garcia JG, Brindley DN. Platelet-released phospholipids link haemostasis and angiogenesis. Cardiovasc Res 2001;49: 588-599.
73. Beer MS, Stanton JA, Salim K, Rigby M, Heavens RP, Smith D, Mcallister G. EDG receptors as a therapeutic target in the nervous system. Ann N Y Acad Sci 2000;905:118-131.
74. Kluk MJ, Hla T. Role of the sphingosine 1-phosphate receptor EDG-1 in vascular smooth muscle cell proliferation and migration. Circ Res 2001;89:496-502.
75. Goetzl EJ, An S. Diversity of cellular receptors and functions for the lysophospholipid growth factors lysophosphatidic acid and sphingosine 1-phosphate. Faseb J 1998;12:1589-1598.
76. Lee MJ, Van Brocklyn JR, Thangada S, Liu CH, Hand AR, Menzeleev R, Spiegel S, Hla T. Sphingosine-1-phosphate as a ligand for the G protein-coupled receptor EDG-1. Science 1998;279: 1552-1555.
77. Kimura T, Watanabe T, Sato K, Kon J, Tomura H, Tamama K, Kuwabara A, Kanda T, Kobayashi I, Ohta H, et al. Sphingosine 1-phosphate stimulates proliferation and migration of human endothelial cells possibly through the lipid receptors, Edg-1 and Edg-3. Biochem J 2000;348 Pt 1:71-76.
78. Lee OH, Kim YM, Lee YM, Moon EJ, Lee DJ, Kim JH, Kim KW, Kwon YG. Sphingosine 1-phosphate induces angiogenesis: Its angiogenic action and signaling mechanism in human umbilical vein endothelial cells. Biochem Biophys Res Commun 1999;264: 743-750.
79. English D, Welch Z, Kovala AT, Harvey K, Volpert OV, Brindley DN, Garcia JG. Sphingosine 1-phosphate released from platelets during clotting accounts for the potent endothelial cell chemotactic activity of blood serum and provides a novel link between hemostasis and angiogenesis. Faseb J 2000;14:2255-2265.
80. Lee MJ, Thangada S, Claffey KP, Ancellin N, Liu CH, Kluk M, Volpi M, Sha'afi RI, Hla T. Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate. Cell 1999;99:301-312.
81. Yatomi Y, Ruan F, Hakomori S, Igarashi Y. Sphingosine-1-phosphate: A platelet-activating sphingolipid released from agonist-stimulated human platelets. Blood 1995;86:193-202.
82. Xiao H, Siddiqui RA, Al-Hassani MH, Sliva D, Kovacs RJ. Phospholipids released from activated platelets improve platelet aggregation and endothelial cell migration. Platelets 2001;12: 163-170.
83. Watson SP, McConnell RT, Lapetina EG. Decanoyl lysophosphatidic acid induces platelet aggregation through an extracellular action. Evidence against a second messenger role for lysophosphatidic acid. Biochem J 1985;232:61-66.
84. Ohmori T, Yatomi Y, Osada M, Ozaki Y. The intracellular action of sphingosine 1-phosphate in GPVI-mediated Ca2+mobilization in platelets. Thromb Res 2005;115:409-415.
85. Ulrych T, Bohm A, Polzin A, Daum G, Nusing RM, Geisslinger G, Hohlfeld T, Schrör K, Rauch BH. Release of sphingosine-1-phosphate from human platelets is dependent on thromboxane formation. J Thromb Haemost 2011;9:790-798.
86. Nachman RL, Rafii S. Platelets, petechiae, and preservation of the vascular wall. N Engl J Med 2008;359:1261-1270.
87. Ho-Tin-Noe B, Demers M, Wagner DD. How platelets safeguard vascular integrity. J Thromb Haemost 2011;9:56-65.
88. Gawaz M, Vogel S. Platelets in tissue repair: Control of apoptosis and interactions with regenerative cells. Blood 2013;122: 2550-2554.
89. Uhrin P, Zaujec J, Breuss JM, Olcaydu D, Chrenek P, Stockinger H, Fuertbauer E, Moser M, Haiko P, Fässler R, et al. Novel function for blood platelets and podoplanin in developmental separation of blood and lymphatic circulation. Blood 2010;115:3997-4005.
90. Suzuki-Inoue K, Inoue O, Ding G, Nishimura S, Hokamura K, Eto K, Kashiwagi H, Tomiyama Y, Yatomi Y, Umemura K, et al. Essential in vivo roles of the C-type lectin receptor CLEC-2: Embryonic/neonatal lethality of CLEC-2-deficient mice by blood/lymphatic misconnections and impaired thrombus formation of CLEC-2-deficient platelets. J Biol Chem 2010;285:24494-24507.
91. Pepper MS. Lymphangiogenesis and tumor metastasis: Myth or reality? Clin Cancer Res 2001;7:462-468.
92. Suzuki-Inoue K, Fuller GL, Garcia A, Eble JA, Pohlmann S, Inoue O, Gartner TK, Hughan SC, Pearce AC, Laing GD, et al. A novel Syk-dependent mechanism of platelet activation by the C-type lectin receptor CLEC-2. Blood 2006;107:542-549.
93. Suzuki-Inoue K, Kato Y, Inoue O, Kaneko MK, Mishima K, Yatomi Y, Yamazaki Y, Narimatsu H, Ozaki Y. Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells. J Biol Chem 2007;282:25993-26001.
94. Watson SP, Herbert JM, Pollitt AY. GPVI and CLEC-2 in hemostasis and vascular integrity. J Thromb Haemost 2010;8: 1456-1467.
95. Schacht V, Ramirez MI, Hong YK, Hirakawa S, Feng D, Harvey N, Williams M, Dvorak AM, Dvorak HF, Oliver G, Detmar M. T1alpha/podoplanin deficiency disrupts normal lymphatic vasculature formation and causes lymphedema. Embo J 2003;22: 3546-3556.
96. Carramolino L, Fuentes J, Garcia-Andres C, Azcoitia V, Riethmacher D, Torres M. Platelets play an essential role in separating the blood and lymphatic vasculatures during embryonic angiogenesis. Circ Res 2010;106:1197-1201.
97. Bertozzi CC, Schmaier AA, Mericko P, Hess PR, Zou Z, Chen M, Chen CY, Xu B, Lu MM, Zhou D, et al. Platelets regulate lymphatic vascular development through CLEC-2-SLP-76 signaling. Blood 2010;116:661-670.
98. Ross MH, Furth J, Bigelow RR. Changes in cellular composition of the lymph caused by ionizing radiations. Blood 1952;7:417-428.
99. Woods MC, Gamble FN, Furth J, Bigelow RR. Control of the postirradiation hemorrhagic state by platelet transfusions. Blood 1953;8:545-553.
100. Osada M, Inoue O, Ding G, Shirai T, Ichise H, Hirayama K, Takano K, Yatomi Y, Hirashima M, Fujii H, et al. Platelet activation receptor CLEC-2 regulates blood/lymphatic vessel separation by inhibiting proliferation, migration, and tube formation of lymphatic endothelial cells. J Biol Chem 2012;287: 22241-22252.
101. Finney BA, Schweighoffer E, Navarro-Nunez L, Benezech C, Barone F, Hughes CE, Langan SA, Lowe KL, Pollitt AY, Mourao-Sa D, et al. CLEC-2 and Syk in the megakaryocytic/platelet lineage are essential for development. Blood 2012;119:1747-1756.
102. Osada M, Suzuki-Inoue K, Inoue O, Ozaki Y. [A role of the platelet receptor CLEC-2 in lymphangiogenesis and its clinical application]. Rinsho Byori 2013;61:318-327.
103. Laurens N, Koolwijk P, de Maat MP. Fibrin structure and wound healing. J Thromb Haemost 2006;4:932-939.
104. Hoffman M, Harger A, Lenkowski A, Hedner U, Roberts HR, Monroe DM. Cutaneous wound healing is impaired in hemophilia B. Blood 2006;108:3053-3060.
105. Werner S, Grose R. Regulation of wound healing by growth factors and cytokines. Physiol Rev 2003;83:835-870.
106. Singer AJ, Clark RA. Cutaneous wound healing. N Engl J Med 1999;341:738-746.
107. Rozman P, Bolta Z. Use of platelet growth factors in treating wounds and soft-tissue injuries. Acta Dermatovenerol Alp Panonica Adriat 2007;16:156-165.
108. Pandya NM, Dhalla NS, Santani DD. Angiogenesis-A new target for future therapy. Vascul Pharmacol 2006;44:265-274.
109. Lieberman JR, Daluiski A, Einhorn TA. The role of growth factors in the repair of bone. Biology and clinical applications. J Bone Joint Surg Am 2002;84-A:1032-1044.
110. Lynch SE, Nixon JC, Colvin RB, Antoniades HN. Role of platelet-derived growth factor in wound healing: Synergistic effects with other growth factors. Proc Natl Acad Sci USA 1987;84: 7696-7700.
111. Margolis DJ, Kantor J, Santanna J, Strom BL, Berlin JA. Effectiveness of platelet releasate for the treatment of diabetic neuropathic foot ulcers. Diabetes Care 2001;24:483-488.
112. Bhanot S, Alex JC. Current applications of platelet gels in facial plastic surgery. Facial Plast Surg 2002;18:27-33.
113. Sanchez M, Anitua E, Azofra J, Andia I, Padilla S, Mujika I. Comparison of surgically repaired Achilles tendon tears using platelet-rich fibrin matrices. Am J Sports Med 2007;35:245-251.
114. Nurden AT, Nurden P, Sanchez M, Andia I, Anitua E. Platelets and wound healing. Front Biosci 2008;13:3532-3548.
115. Ho-Tin-Noe B, Goerge T, Cifuni SM, Duerschmied D, Wagner DD. Platelet granule secretion continuously prevents intratumor hemorrhage. Cancer Res 2008;68:6851-6858.
116. Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest 2005;115:3378-3384.
117. Milovanovic M, Nilsson E, Jaremo P. Relationships between platelets and inflammatory markers in rheumatoid arthritis. Clin Chim Acta 2004;343:237-240.
118. Yamashiro K, Tsujikawa A, Ishida S, Usui T, Kaji Y, Honda Y, Ogura Y, Adamis AP. Platelets accumulate in the diabetic retinal vasculature following endothelial death and suppress blood-retinal barrier breakdown. Am J Pathol 2003;163:253-259.
119. Berrettini M, Parise P, Constantini V, Grasselli S, Nenci GG. Platelet activation in psoriasis. Thromb Haemost 1985;53:195-197.
120. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005;438:967-974.
121. Lambrechts D, Storkebaum E, Carmeliet P. VEGF: Necessary to prevent motoneuron degeneration, sufficient to treat ALS? Trends Mol Med 2004;10:275-282.
122. Duley L, Henderson-Smart DJ, Knight M, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev 2004;(1):CD004659.
123. Peterson JE, Zurakowski D, Italiano Jr JE, Michel LV, Fox L, Klement GL, Folkman J. Normal ranges of angiogenesis regulatory proteins in human platelets. Am J Hematol 2010;85:487-493.
124. Jorgensen L. The role of platelets in the initial stages of atherosclerosis. J Thromb Haemost 2006;4:1443-1449.
125. Massberg S, Brand K, Gruner S, Page S, Muller E, Muller I, Bergmeier W, Richter T, Lorenz M, Konrad I, et al. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med 2002;196:887-896.
126. Nieswandt B, Aktas B, Moers A, Sachs UJ. Platelets in atherothrombosis: Lessons from mouse models. J Thromb Haemost 2005;3:1725-1736.
127. Burger PC, Wagner DD. Platelet P-selectin facilitates atherosclerotic lesion development. Blood 2003;101:2661-2666.
128. Methia N, Andre P, Denis CV, Economopoulos M, Wagner DD. Localized reduction of atherosclerosis in von Willebrand factordeficient mice. Blood 2001;98:1424-1428.
129. Gawaz M, Stellos K, Langer HF. Platelets modulate atherogenesis and progression of atherosclerotic plaques via interaction with progenitor and dendritic cells. J Thromb Haemost 2008;6:235-242.
130. Li N. CD4+T cells in atherosclerosis: Regulation by platelets. Thromb Haemost 2013;109:980-990.
131. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331: 1480-1487.
132. Hammes HP, Lin J, Bretzel RG, Brownlee M, Breier G. Upregulation of the vascular endothelial growth factor/vascular endothelial growth factor receptor system in experimental background diabetic retinopathy of the rat. Diabetes 1998;47:401-406.
133. Ishibashi T, Tanaka K, Taniguchi Y. Platelet aggregation and coagulation in the pathogenesis of diabetic retinopathy in rats. Diabetes 1981;30:601-606.
134. Simo R, Carrasco E, Garcia-Ramirez M, Hernandez C. Angiogenic and anti-angiogenic factors in proliferative diabetic retinopathy. Curr Diabetes Rev 2006;2:71-98.
135. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971;285:1182-1186.
136. Ringvall M, Thulin A, Zhang L, Cedervall J, Tsuchida-Straeten N, Jahnen-Dechent W, Siegbahn A, Olsson AK. Enhanced platelet activation mediates the accelerated angiogenic switch in mice lacking histidine-rich glycoprotein. PLoS One 2011;6:e14526.
137. Kitchens CS, Weiss L. Ultrastructural changes of endothelium associated with thrombocytopenia. Blood 1975;46:567-578.
138. Aird WC. Molecular heterogeneity of tumor endothelium. Cell Tissue Res 2009;335:271-281.
139. Jain RK. Determinants of tumor blood flow: A review. Cancer Res 1988;48:2641-2658.
140. Ho-Tin-Noe B, Carbo C, Demers M, Cifuni SM, Goerge T, Wagner DD. Innate immune cells induce hemorrhage in tumors during thrombocytopenia. Am J Pathol 2009;175:1699-1708.
141. Manegold PC, Hutter J, Pahernik SA, Messmer K, Dellian M. Platelet-endothelial interaction in tumor angiogenesis and microcirculation. Blood 2003;101:1970-1976.
142. Nieswandt B, Hafner M, Echtenacher B, Mannel DN. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res 1999;59:1295-1300.
143. Palumbo JS, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck KW, Jirousková M, Degen JL. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood 2005;105: 178-185.
144. Kopp HG, Placke T, Salih HR. Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity. Cancer Res 2009;69: 7775-7783.
145. Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymallike transition and promotes metastasis. Cancer Cell 2011;20: 576-590.
146. Hall CL, Dubyk CW, Riesenberger TA, Shein D, Keller ET, van Golen KL. Type I collagen receptor (alpha2beta1) signaling promotes prostate cancer invasion through RhoC GTPase. Neoplasia 2008;10:797-803.
147. Chen YQ, Trikha M, Gao X, Bazaz R, Porter AT, Timar J, Honn KV. Ectopic expression of platelet integrin alphaIIb beta3 in tumor cells from various species and histological origin. Int J Cancer 1997;72:642-648.
148. Gasic GJ. Role of plasma, platelets, and endothelial cells in tumor metastasis. Cancer Metastasis Rev 1984;3:99-114.
149. Amirkhosravi A, Mousa SA, Amaya M, Blaydes S, Desai H, Meyer T, Francis JL. Inhibition of tumor cell-induced platelet aggregation and lung metastasis by the oral GpIIb/IIIa antagonist XV454. Thromb Haemost 2003;90:549-554.
150. Jain S, Zuka M, Liu J, Russell S, Dent J, Guerrero JA, Forsyth J, Maruszak B, Gartner TK, Felding-Habermann B, Ware J. Platelet glycoprotein Ib alpha supports experimental lung metastasis. Proc Natl Acad Sci USA 2007;104:9024-9028.
151. Jain S, Russell S, Ware J. Platelet glycoprotein VI facilitates experimental lung metastasis in syngenic mouse models. J Thromb Haemost 2009;7:1713-1717.
152. Ludwig RJ, Boehme B, Podda M, Henschler R, Jager E, Tandi C, Boehncke WH, Zollner TM, Kaufmann R, Gille J. Endothelial P-selectin as a target of heparin action in experimental melanoma lung metastasis. Cancer Res 2004;64:2743-2750.
153. Karpatkin S, Ambrogio C, Pearlstein E. The role of tumor-induced platelet aggregation, platelet adhesion and adhesive proteins in tumor metastasis. Prog Clin Biol Res 1988;283:585-606.
154. Erpenbeck L, Nieswandt B, Schon M, Pozgajova M, Schon MP. Inhibition of platelet GPIb alpha and promotion of melanoma metastasis. J Invest Dermatol 2010;130:576-586.
155. Borsig L. The role of platelet activation in tumor metastasis. Expert Rev Anticancer Ther 2008;8:1247-1255.
156. Erpenbeck L, Schon MP. Deadly allies: The fatal interplay between platelets and metastasizing cancer cells. Blood 2010;115: 3427-3436.
157. Jain S, Harris J, Ware J. Platelets: Linking hemostasis and cancer. Arterioscler Thromb Vasc Biol 2010;30:2362-2367.
158. Coupland LA, Chong BH, Parish CR. Platelets and p-selectin control tumor cell metastasis in an organ-specific manner and independently of NK cells. Cancer Res 2012;72:4662-4671.
159. Schumacher D, Strilic B, Sivaraj KK, Wettschureck N, Offermanns S. Platelet-derived nucleotides promote tumor-cell transendothelial migration and metastasis via P2Y2 receptor. Cancer Cell 2013;24: 130-137.
160. Kerr BA, McCabe NP, Feng W, Byzova TV. Platelets govern premetastatic tumor communication to bone. Oncogene 2013;32: 4319-4324.
161. Zhang W, Dang S, Hong T, Tang J, Fan J, Bu D, Sun Y, Wang Z, Wisniewski T. A humanized single-chain antibody against beta 3 integrin inhibits pulmonary metastasis by preferentially fragmenting activated platelets in the tumor microenvironment. Blood 2012; 120:2889-2898.
162. Egan K, Crowley D, Smyth P, O'Toole S, Spillane C, Martin C, Gallagher M, Canney A, Norris L, Conlon N, et al. Platelet adhesion and degranulation induce pro-survival and pro-angiogenic signalling in ovarian cancer cells. PLoS One 2011;6:e26125.
163. Amirkhosravi A, Amaya M, Siddiqui F, Biggerstaff JP, Meyer TV, Francis JL. Blockade of GpIIb/IIIa inhibits the release of vascular endothelial growth factor (VEGF) from tumor cell-activated platelets and experimental metastasis. Platelets 1999;10:285-292.
164. Engebraaten O, Trikha M, Juell S, Garman-Vik S, Fodstad O. Inhibition of in vivo tumour growth by the blocking of host alpha(v)beta3 and alphaII(b)beta3 integrins. Anticancer Res 2009; 29:131-137.
165. Battinelli EM, Markens BA, Italiano Jr JE. Release of angiogenesis regulatory proteins from platelet alpha granules: Modulation of physiologic and pathologic angiogenesis. Blood 2011;118: 1359-1369.
166. Battinelli EM, Markens BA, Kulenthirarajan RA, Machlus KR, Flaumenhaft R, Italiano Jr JE. Anticoagulation inhibits tumor cell mediated release of platelet angiogenic proteins and diminishes platelet angiogenic response. Blood 2014;123:101-112.
167. Bluff JE, Brown NJ, Reed MW, Staton CA. Tissue factor, angiogenesis and tumour progression. Breast Cancer Res 2008; 10:204.
168. Callander NS, Varki N, Rao LV. Immunohistochemical identification of tissue factor in solid tumors. Cancer 1992;70:1194-1201.
169. Mechtcheriakova D, Wlachos A, Holzmuller H, Binder BR, Hofer E. Vascular endothelial cell growth factor-induced tissue factor expression in endothelial cells is mediated by EGR-1. Blood 1999; 93:3811-3823.
170. Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, Rupairmoole R, Armaiz-Pena GN, Pecot CV, Coward J, et al. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med 2012;366:610-618.
171. Salgado R, Vermeulen PB, Benoy I, Weytjens R, Huget P, Van Marck E, Dirix LY. Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients. Br J Cancer 1999;80:892-897.
172. Caine GJ, Lip GY, Blann AD. Platelet-derived VEGF, Flt-1, angiopoietin-1 and P-selectin in breast and prostate cancer: Further evidence for a role of platelets in tumour angiogenesis. Ann Med 2004;36:273-277.
173. Salven P, Orpana A, Joensuu H. Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor. Clin Cancer Res 1999;5:487-491.
174. Gonzalez FJ, Rueda A, Sevilla I, Alonso L, Villarreal V, Torres E, Alba E. Shift in the balance between circulating thrombospondin-1 and vascular endothelial growth factor in cancer patients: Relationship to platelet alpha-granule content and primary activation. Int J Biol Markers 2004;19:221-228.
175. Helley D, Banu E, Bouziane A, Banu A, Scotte F, Fischer AM, Oudard S. Platelet microparticles: A potential predictive factor of survival in hormone-refractory prostate cancer patients treated with docetaxel-based chemotherapy. Eur Urol 2009;56: 479-484.
176. Lip GY, Chin BS, Blann AD. Cancer and the prothrombotic state. Lancet Oncol 2002;3:27-34.
177. Fontaine E, McShane J, Page R, Shackcloth M, Mediratta N, Carr M, Soorae A, Poullis M. Aspirin and non-small cell lung cancer resections: Effect on long-term survival. Eur J Cardiothorac Surg 2010;38:21-26.
178. Holmes MD, Chen WY, Li L, Hertzmark E, Spiegelman D, Hankinson SE. Aspirin intake and survival after breast cancer. J Clin Oncol 2010;28:1467-1472.
179. Holmes CE, Huang JC, Pace TR, Howard AB, Muss HB. Tamoxifen and aromatase inhibitors differentially affect vascular endothelial growth factor and endostatin levels in women with breast cancer. Clin Cancer Res 2008;14:3070-3076.
180. Creagan ET, Twito DI, Johansson SL, Schaid DJ, Johnson PS, Flaum MA, Buroker TR, Geeraerts LH, Veeder MH, Gesme Jr DH, et al. A randomized prospective assessment of recombinant leukocyte A human interferon with or without aspirin in advanced renal adenocarcinoma. J Clin Oncol 1991;9: 2104-2109.
181. Lipton A, Scialla S, Harvey H, Dixon R, Gordon R, Hamilton R, Ramsey H, Weltz M, Heckard R, White D. Adjuvant antiplatelet therapy with aspirin in colo-rectal cancer. J Med 1982;13:419-429.
182. Kakkar AK, Levine MN, Kadziola Z, Lemoine NR, Low V, Patel HK, Rustin G, Thomas M, Quigley M, Williamson RC. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: The fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004;22:1944-1948.
183. Lemoine NR. Antithrombotic therapy in cancer. J Clin Oncol 2005; 23:2119-2120.
184. Nash GF, Walsh DC, Kakkar AK. The role of the coagulation system in tumour angiogenesis. Lancet Oncol 2001;2:608-613.
185. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8:592-603.
186. Bridges EM, Harris AL. The angiogenic process as a therapeutic target in cancer. Biochem Pharmacol 2011;81:1183-1191.
187. Handsley MM, Edwards DR. Metalloproteinases and their inhibitors in tumor angiogenesis. Int J Cancer 2005;115:849-860.
188. Sato N, Beitz JG, Kato J, Yamamoto M, Clark JW, Calabresi P, Raymond A, Frackelton Jr AR. Platelet-derived growth factor indirectly stimulates angiogenesis in vitro. Am J Pathol 1993;142: 1119-1130.
189. Ueki N, Nakazato M, Ohkawa T, Ikeda T, Amuro Y, Hada T, Higashino K. Excessive production of transforming growth-factor beta 1 can play an important role in the development of tumorigenesis by its action for angiogenesis: Validity of neutralizing antibodies to block tumor growth. Biochim Biophys Acta 1992; 1137:189-196.
190. Nakamura T, Teramoto H, Ichihara A. Purification and characterization of a growth factor from rat platelets for mature parenchymal hepatocytes in primary cultures. Proc Natl Acad Sci USA 1986;83: 6489-6493.
191. Rofstad EK, Halsor EF. Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts. Cancer Res 2000;60: 4932-4938.
192. Zamani A, Qu Z. Serotonin activates angiogenic phosphorylation signaling in human endothelial cells. FEBS Lett 2012;586: 2360-2365.
193. Bertrand-Duchesne MP, Grenier D, Gagnon G. Epidermal growth factor released from platelet-rich plasma promotes endothelial cell proliferation in vitro. J Periodontal Res 2010;45: 87-93.
194. Tashiro Y, Nishida C, Sato-Kusubata K, Ohki-Koizumi M, Ishihara M, Sato A, Gritli I, Komiyama H, Sato Y, Dan T, et al. Inhibition of PAI-1 induces neutrophil-driven neoangiogenesis and promotes tissue regeneration via production of angiocrine factors in mice. Blood 2012;119:6382-6393.
195. Roberts AB, Sporn MB. Regulation of endothelial cell growth, architecture, and matrix synthesis by TGF-beta. Am Rev Respir Dis 1989;140:1126-1128.
196. Struyf S, Burdick MD, Proost P, Van Damme J, Strieter RM. Platelets release CXCL4L1, a nonallelic variant of the chemokine platelet factor-4/CXCL4 and potent inhibitor of angiogenesis. Circ Res 2004;95:855-857.